Literature DB >> 28865151

Immune evasion mechanisms of human papillomavirus: An update.

Alina Steinbach1,2, Angelika B Riemer1,2.   

Abstract

Human papillomavirus (HPV) is the most frequently sexually transmitted agent in the world. It can cause cervical and other anogenital malignancies, and oropharyngeal cancer. HPV has the unique ability to persist in the host's epithelium for a long time-longer than most viruses do-which is necessary to complete its replication cycle. To this end, HPV has developed a variety of immune evasion mechanisms, which unfortunately also favor the progression of the disease from infection to chronic dysplasia and eventually to cancer. This article summarizes the current knowledge about HPV immune evasion strategies. A special emphasis lies in HPV-mediated changes of the antigen processing machinery, which is generating epitopes for T cells and contributes to the detectability of infected cells.
© 2017 UICC.

Entities:  

Mesh:

Year:  2017        PMID: 28865151     DOI: 10.1002/ijc.31027

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  31 in total

Review 1.  Epidemiologic perspectives on immunosuppressed populations and the immunosurveillance and immunocontainment of cancer.

Authors:  Eric A Engels
Journal:  Am J Transplant       Date:  2019-07-08       Impact factor: 8.086

2.  Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model.

Authors:  Sebastian Kruse; Marleen Büchler; Philipp Uhl; Max Sauter; Philipp Scherer; Tammy C T Lan; Samantha Zottnick; Alexandra Klevenz; Ruwen Yang; Frank Rösl; Walter Mier; Angelika B Riemer
Journal:  Oncoimmunology       Date:  2018-10-29       Impact factor: 8.110

3.  Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease.

Authors:  Diane M Da Silva; Joseph G Skeate; Elena Chavez-Juan; Kim P Lühen; Jiun-Ming Wu; Chia-Mao Wu; W Martin Kast; KinKai Hwang
Journal:  Vaccine       Date:  2019-04-19       Impact factor: 3.641

Review 4.  Consideration of underlying immunodeficiency in refractory or recalcitrant warts: A review of the literature.

Authors:  J Zampella; B Cohen
Journal:  Skin Health Dis       Date:  2022-02-09

Review 5.  Mechanisms of persistence by small DNA tumor viruses.

Authors:  Nathan A Krump; Wei Liu; Jianxin You
Journal:  Curr Opin Virol       Date:  2018-10-01       Impact factor: 7.090

6.  The Human Papillomavirus E6 Oncoprotein Targets USP15 and TRIM25 To Suppress RIG-I-Mediated Innate Immune Signaling.

Authors:  Cindy Chiang; Eva-Katharina Pauli; Jennifer Biryukov; Katharina F Feister; Melissa Meng; Elizabeth A White; Karl Münger; Peter M Howley; Craig Meyers; Michaela U Gack
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

7.  Cytokine response following perturbation of the cervicovaginal milieu during HPV genital infection.

Authors:  Christian Selinger; Massilva Rahmoun; Carmen Lia Murall; Claire Bernat; Vanina Boué; Marine Bonneau; Christelle Graf; Sophie Grasset; Soraya Groc; Jacques Reynes; Christophe Hirtz; Nathalie Jacobs; Samuel Alizon
Journal:  Immunol Res       Date:  2021-04-30       Impact factor: 2.829

Review 8.  Tumor Immunity and Immunotherapy for HPV-Related Cancers.

Authors:  Achraf A Shamseddine; Bharat Burman; Nancy Y Lee; Dmitriy Zamarin; Nadeem Riaz
Journal:  Cancer Discov       Date:  2021-05-14       Impact factor: 39.397

Review 9.  Pathogenic Role of Immune Evasion and Integration of Human Papillomavirus in Oropharyngeal Cancer.

Authors:  Takashi Hatano; Daisuke Sano; Hideaki Takahashi; Nobuhiko Oridate
Journal:  Microorganisms       Date:  2021-04-21

Review 10.  The interplay between the vaginal microbiome and innate immunity in the focus of predictive, preventive, and personalized medical approach to combat HPV-induced cervical cancer.

Authors:  Erik Kudela; Alena Liskova; Marek Samec; Lenka Koklesova; Veronika Holubekova; Tomas Rokos; Erik Kozubik; Terezia Pribulova; Kevin Zhai; Dietrich Busselberg; Peter Kubatka; Kamil Biringer
Journal:  EPMA J       Date:  2021-05-18       Impact factor: 8.836

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.